Hunter Diabetes Centre | Merewether, Australia

Research site

(Unclaimed)

Location

Level 1, 41 Llewellyn Street, Merewether, New South Wales, Australia

Site insights

Top conditions

Top treatments

Sugar

BI 456906

Metformin

Semaglutide

Cagrilintide

Tirzepatide

Fenofibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 17 total trials

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight....

Not yet enrolling

Obesity

Type 2 Diabetes

Drug: Cagrisema

Drug: Semaglutide

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both (REIMAGINE 5)

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medi...

Active, not recruiting

Diabetes Mellitus, Type 2

Drug: Cagrilintide

Drug: Semaglutide

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19...

Active, not recruiting

COVID-19

Biological: Fluzone High Dose

Biological: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant

Locations recently updated

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2...

Enrolling

Obesity

Drug: NNC0487-0111

Drug: Placebo (matched to NNC0487-0111)

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2...

Enrolling

Obesity

Drug: NNC0487-0111

Drug: Placebo (matched to NNC0487-0111)

The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. (FAME 1 EYE)

The purpose of this study is to evaluate the potential benefits of 145 mg of daily fenofibrate in adults with type 1 diabetes mellitus and pre-existi...

Active, not recruiting

Diabetic Nephropathies

Type 1 Diabetes Mellitus

Drug: Inert lactose placebo

Drug: Fenofibrate

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide (RENEW 1)

This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Cagrilintide